111 related articles for article (PubMed ID: 11202195)
1. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
[TBL] [Abstract][Full Text] [Related]
3. Miltefosine: new preparation. Solution for cutaneous application.
Prescrire Int; 1998 Feb; 7(33):5-6. PubMed ID: 10183390
[TBL] [Abstract][Full Text] [Related]
4. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Acta Oncol; 2005; 44(7):773-7. PubMed ID: 16227173
[No Abstract] [Full Text] [Related]
5. Miltefosine in recurrent cutaneous breast cancer.
Clive S; Leonard RC
Lancet; 1997 Mar; 349(9052):621-2. PubMed ID: 9057742
[No Abstract] [Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
9. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Clive S; Gardiner J; Leonard RC
Cancer Chemother Pharmacol; 1999; 44 Suppl():S29-30. PubMed ID: 10602908
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Smorenburg CH; Seynaeve C; Bontenbal M; Planting AS; Sindermann H; Verweij J
Anticancer Drugs; 2000 Nov; 11(10):825-8. PubMed ID: 11142690
[TBL] [Abstract][Full Text] [Related]
11. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Unger C; Peukert M; Sindermann H; Hilgard P; Nagel G; Eibl H
Cancer Treat Rev; 1990 Sep; 17(2-3):243-6. PubMed ID: 2272039
[TBL] [Abstract][Full Text] [Related]
12. 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers.
Eilender D; LoRusso P; Thomas L; McCormick C; Rodgers AH; Hooper CL; Tornyos K; Krementz ET; Parker S; Morgan LR
Cancer Chemother Pharmacol; 2006 Jun; 57(6):719-26. PubMed ID: 16184382
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
14. Factors determining outcome after third line chemotherapy for metastatic breast cancer.
Banerji U; Kuciejewska A; Ashley S; Walsh G; O'Brien M; Johnston S; Smith I
Breast; 2007 Aug; 16(4):359-66. PubMed ID: 17509879
[TBL] [Abstract][Full Text] [Related]
15. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
Eichbaum MH; Schuetz F; Khbeis T; Lauschner I; Foerster F; Sohn C; Schneeweiss A
Anticancer Drugs; 2007 Sep; 18(8):963-8. PubMed ID: 17667603
[TBL] [Abstract][Full Text] [Related]
16. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
17. [Use of vindesine in lymphangitic-type cutaneous recurrence of breast cancer].
Palangie T; Jouve M; Giralt E; Bretaudeau B; Pouillart P
Bull Cancer; 1983; 70(5):437-8. PubMed ID: 6582941
[No Abstract] [Full Text] [Related]
18. [Spectrographic studies on the radioresistance of Miltex and miltefosine].
Bollmann G; Paukisch H; Bothe E; Strate W; Gademann G
Strahlenther Onkol; 1997 Apr; 173(4):230-5. PubMed ID: 9148435
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of integrative cancer care in advanced metastatic breast cancer.
Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
